Skip To Main Content
Nancy A Rigotti on Muck Rack

Nancy A Rigotti

As seen in: Journal of Health Psychology, PLOS ONE, MDPI, Taylor & Francis Online, JAMA (The Journal of the American Medical Association), JAMA Internal Medicine Author Interviews, JAMA: Journal of the American Medical Association, JAMA Health Forum Conversations, Medscape, The New England Journal of Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nancy A

Contact Nancy A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nicotine E-Cigarettes for Cigarette Smoking Cessation : Recommendations to US-Based Clinicians

|
By Eleanor Leavens, Kinsey N Pebley, Tracy Smith Verified, Jasjit S. Ahluwalia, Mariel S. Bello, Krysten W. Bold, Jennifer Cantrell, Matthew J Carpenter, Patricia A. Cioe, Nicholas J Felicione, Alys Havard, Larry Hawk, Jesse T. Kaye, Elias M. Klemperer, Bethea A. Kleykamp, Nicola Lindson, Erin McClure, Hayden McRobbie, Cara Murphy, Nancy A Rigotti, Natalie Walker, Min-Jeong Yang, Alana M. Rojewski, Adrienne Johnson
| JAMA: Journal of the American Medical Association Verified
Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians Abstract Importance Cigarette smoking, maintained predominantly by nicotine dependence, is a long-term and relapsing behavior that continues to be a leading cause of preventable death and disease worldwide. E-cigarettes with nicotine are less harmful than cigarettes and have been shown to be more effective for smoking cessation than US Food and Drug Administration–approved nicotine replacement therapies.
Open in Who Shared Issue with article?

An evaluation of cytisinicline for smoking cessation in adult smokers

|
By Nancy A Rigotti, Neal L Benowitz
| Taylor & Francis Online
ABSTRACT Introduction Cigarette smoking is the world’s leading preventable cause of death. With no new smoking cessation pharmacotherapy approved since 2006, the 29 million US adults who smoke need new treatment options. Cytisinicline, a partial agonist at α4β2 neuronal nicotinic acetylcholine receptors, is the name of a new dosing regimen of cytisine, a smoking cessation pharmacotherapy that has been sold for decades in Eastern Europe but is currently unavailable in the US.
Open in Who Shared Issue with article?

Cigarette smoking in PrEP recipients: a challenge and an opportunity

|
By Jonathan Shuter, Albert Einstein College, Nancy A Rigotti, Andrea H. Weinberger
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Helleberg, M ∙ Afzal, S ∙ Kronborg, G ∙ et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study Clin Infect Dis. 2013; 56:727-734 2. Asfar, T ∙ Perez, A ∙ Shipman, P ∙ et al. National estimates of prevalence, time-trend, and correlates of smoking in US people living with HIV (NHANES 1999–2016) Nicotine Tob Res. 2021; 23:1308-1317 3.
Open in Who Shared Issue with article?
See all 31 licensed articles (38 Total)